GLP1RGlucagon-Like Peptide 1 Receptor
References in periodicals archive ?
Robert Lutjens, head of biology at Addex Pharmaceuticals, said that GIPR and GLP1R are present together in pancreatic and nerve cells, and their roles in Type 2 diabetes make them important targets for the development of new drugs.
The development of the GLP1R agonists is based on the discovery that the incretin system is integrally involved in regulating glucose homeostasis.
TransTech's current diabetes and obesity portfolio includes orally administered and novel therapeutic development candidates targeting PTP1b inhibitors, AgRP inhibitors, GLP1R agonists, AMPK activators and glucokinase activators.